Cargando…
Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development
Type 1 diabetes (T1D) is an autoimmune disease in which the β-cells of the pancreas are attacked by the host’s immune system, ultimately resulting in hyperglycemia. It is a complex multifactorial disease postulated to result from a combination of genetic and environmental factors. In parallel with i...
Autores principales: | Du, Chenping, Whiddett, Rani O., Buckle, Irina, Chen, Chen, Forbes, Josephine M., Fotheringham, Amelia K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9657002/ https://www.ncbi.nlm.nih.gov/pubmed/36359899 http://dx.doi.org/10.3390/cells11213503 |
Ejemplares similares
-
Advanced Glycation End Products (AGEs) and Chronic Kidney Disease: Does the Modern Diet AGE the Kidney?
por: Fotheringham, Amelia K., et al.
Publicado: (2022) -
Advanced glycation end products as predictors of renal function in youth with type 1 diabetes
por: Forbes, Josephine M., et al.
Publicado: (2021) -
Modulation of the Cellular Expression of Circulating Advanced Glycation End-Product Receptors in Type 2 Diabetic Nephropathy
por: Sourris, Karly C., et al.
Publicado: (2010) -
Alpha cell receptor for advanced glycation end products associate with glucagon expression in type 1 diabetes
por: Leung, Sherman S., et al.
Publicado: (2023) -
Perinatal exposure to high dietary advanced glycation end products in transgenic NOD8.3 mice leads to pancreatic beta cell dysfunction
por: Borg, Danielle J., et al.
Publicado: (2017)